Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ATP1A1 | P05023 | 2/20 | 0.31 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.31 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.31 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.31 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.31 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.31 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.31 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6940847 | 0.87 | — | — | |
| SCHEMBL4665492 | 0.78 | TRPA1 (0.33) | TRPA1SLC18A3SIGMAR1 | |
| SCHEMBL4663718 | 0.78 | OPRL1 (0.34) | TRPA1SLC18A3SIGMAR1ATP1A1ATP1B1 | |
| SCHEMBL4663447 | 0.76 | OPRM1 (0.38) | TRPA1SLC18A3SIGMAR1 | |
| SCHEMBL4664152 | 0.74 | OPRD1 (0.41) | TRPA1ATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL4665487 | 0.74 | PSEN1 (0.32) | TRPA1 | |
| SCHEMBL4663548 | 0.74 | OPRM1 (0.41) | TRPA1SIGMAR1ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL4664132 | 0.74 | OPRM1 (0.41) | SIGMAR1 | |
| SCHEMBL4663964 | 0.74 | OPRM1 (0.39) | SLC18A3SIGMAR1 | |
| SCHEMBL4663546 | 0.72 | OPRD1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1571140-B1 | C-substituted cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2008-11-12 | — | — | EP | claimed |
| US-7273952-B2 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2007-09-25 | — | — | US | claimed |
| US-20030232891-A1 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2003-12-18 | — | — | US | claimed |
| EP-1571140-B1 | C-substituted cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2008-11-12 | — | — | EP | disclosed |
| US-7273952-B2 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2007-09-25 | — | — | US | disclosed |
| EP-1368299-B1 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2006-07-26 | — | — | EP | disclosed |
| EP-1571140-A1 | C-substituted cyclohexylmethylamine derivatives | Grünenthal GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-20030232891-A1 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2003-12-18 | — | — | US | disclosed |
| EP-1368299-A2 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002030870-A2 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232891-A1 | Substituted C-cyclohexylmethylamine derivatives | CNR2, CNR1, HNMT | TRPA1 155/4885SLC18A3 1058/4885SIGMAR1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.